- FDA Prioritizes Review of Roche's Inavolisib for PIK3CA+ Breast ...🔍
- Selecting Second|Line Therapy for Metastatic HR|Positive/HER2 ...🔍
- FDA grants Breakthrough Therapy Designation to Roche's inavolisib ...🔍
- FDA grants priority review to Roche's inavolisib for advanced ...🔍
- FDA Approves Genentech's Itovebi🔍
- Inavolisib Regimen Approved for Certain Breast Cancers🔍
- Roche's Inavolisib PI3K Inhibitor receives FDA priority review for ...🔍
- FDA Grants Lenalidomide/Rituximab Priority Review for Non|Hogkin ...🔍
FDA Grants Priority Review to Inavolisib in HR /HER2
FDA Prioritizes Review of Roche's Inavolisib for PIK3CA+ Breast ...
Roche's inavolisib receives FDA Priority Review for use with palbociclib and fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative ...
Selecting Second-Line Therapy for Metastatic HR-Positive/HER2 ...
There are ongoing trials looking at next-generation PI3K inhibitors, such as inavolisib ... In addition, the FDA has granted priority review for ...
FDA grants Breakthrough Therapy Designation to Roche's inavolisib ...
A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2– Metastatic Breast Cancer. Int J Breast Cancer. 2020;2020 ...
FDA grants priority review to Roche's inavolisib for advanced ...
FDA grants priority review to Roche's inavolisib for advanced hormone receptor positive, HER2 negative breast cancer with a PIK3CA mutation.
FDA Approves Genentech's Itovebi, a Targeted Treatment for ...
FDA Approves Genentech's Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA ...
Inavolisib Regimen Approved for Certain Breast Cancers | Research
PI3K inhibitor inavolisib is approved as part of a regimen for certain patients whose breast cancer recurred on or after endocrine therapy.
Roche's Inavolisib PI3K Inhibitor receives FDA priority review for ...
This combination therapy is designed for adult patients with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)- ...
FDA Grants Lenalidomide/Rituximab Priority Review for Non-Hogkin ...
Inavolisib (Itovebi) plus palbociclib (Ibrance) and fulvestrant ...
FDA grants Priority Review to Roche's inavolisib for advanced ...
Bulletin · Roche - FDA grants Priority Review to Roche's inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a ...
Roche Holding AG: FDA grants Priority Review to Roche's inavolisib ...
[1] Fillbrunn M, et al. PIK3CA mutation status, progression and survival in advanced HR+/HER2- breast cancer: a meta-analysis of published clinical trials. BMC ...
FDA grants priority review to glofitamab for R/R LBCL
FDA has accepted Genentech's Biologics License Application and granted priority review for glofitamab, an investigational CD20xCD3 T-cell ...
FDA Grants Lorlatinib a Priority Review for Lung Cancer Treatment
Itovebi, combined with Ibrance and Faslodex, significantly improved progression-free survival in PIK3CA-mutated, HR-positive, HER2-negative ...
Cancer immunotherapy target 'alpha' (Recursion Pharmaceuticals)
FDA grants Breakthrough Therapy Designation to Roche's inavolisib for ... HER2-negative (HR+/HER2–) metastatic breast cancer. Presented at San Antonio ...